U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H23N3O7S.Na.H
Molecular Weight 497.4986
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERTAPENEM SODIUM

SMILES

C[C@]1([H])[C@]2([H])[C@@]([H])([C@@]([H])(C)O)C(=O)N2C(=C1S[C@@]3([H])C[C@@]([H])(C(=Nc4cccc(c4)C(=O)O)[O-])NC3)C(=O)O.[Na+]

InChI

InChIKey=ZXNAQFZBWUNWJM-HRXMHBOMSA-M
InChI=1S/C22H25N3O7S.Na/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30;/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32);/q;+1/p-1/t9-,10-,13+,14+,15-,16-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H23N3O7S
Molecular Weight 473.5009
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/ppa/ertapenem.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22 | http://www.rxlist.com/invanz-drug.htm

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis in females (2.1%), phlebitis/thrombophlebitis (1.3%), and vomiting (1.1%). The coadministration with probenecid to extend the half-life of ertapenem is not recommended.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0AD65
Gene ID: 945240.0
Gene Symbol: mrdA
Target Organism: Escherichia coli (strain K12)
Target ID: P0AD68
Gene ID: 944799.0
Gene Symbol: ftsI
Target Organism: Escherichia coli (strain K12)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
75.7 μg/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
70.6 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
155 μg/mL
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
663.1 ug/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
506.4 μg × h/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
541.8 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6225 ug*h/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.8 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4 h
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.3 h
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g 1 times / day steady, intravenous
Highest studied dose
Dose: 3 g, 1 times / day
Route: intravenous
Route: steady
Dose: 3 g, 1 times / day
Sources:
healthy, 18-49 years
Health Status: healthy
Age Group: 18-49 years
Sex: M+F
Sources:
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Encephalopathy...
AEs leading to
discontinuation/dose reduction:
Encephalopathy (1 patient)
Sources:
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hallucinations, Delirium...
AEs leading to
discontinuation/dose reduction:
Hallucinations (1 patient)
Delirium (1 patient)
Sources:
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Disc. AE: Rash, Confusion...
AEs leading to
discontinuation/dose reduction:
Rash (1 patient)
Confusion (1 patient)
Seizure (1 patient)
Thrombocytopenia (1 patient)
Sources: Page: p. 184
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Other AEs: Diarrhea, Dizziness...
Other AEs:
Diarrhea (1 patient)
Dizziness (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Encephalopathy 1 patient
Disc. AE
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Delirium 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Hallucinations 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Confusion 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Rash 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Seizure 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Thrombocytopenia 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Diarrhea 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Dizziness 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no
no
no
yes [IC50 56.2 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
2002 Winter
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
2002 Winter
[Efficacy of invanz proven in the treatment of intra-abdominal infections in one of the largest studies yet conducted on surgical patients].
2003
Ertapenem: a review of its use in the management of bacterial infections.
2003
[Problems of pharmacotherapy of infections in the aged].
2003 Aug
NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America.
2003 Aug
Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000.
2003 Aug
[New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
2003 Jul-Sep
Ertapenem therapy for community-acquired pneumonia in the elderly.
2003 Nov
In vitro activity of ertapenem against anaerobes isolated from the respiratory tract.
2003 Oct
Ertapenem, the first of a new group of carbapenems.
2003 Oct
Properties and potential of ertapenem.
2003 Sep
Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia.
2004
Gateways to clinical trials.
2004 Apr
New therapies for pneumococcal meningitis.
2004 Apr
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
2004 Feb
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
2004 Jan
Stability and compatibility of reconstituted ertapenem with commonly used i.v. infusion and coinfusion solutions.
2004 Jan 1
Column-switching technique for the sensitive determination of ertapenem in human cerebrospinal fluid using liquid chromatography and ultraviolet absorbance detection.
2004 Jan 5
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
2004 Jul
Activity of ertapenem against Neisseria gonorrhoeae.
2004 Jul
Gateways to clinical trials.
2004 Jun
Emerging issues in infective endocarditis.
2004 Jun
Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.
2004 Jun
Safety and tolerability of ertapenem.
2004 Jun
Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
2004 Jun
Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
2004 Jun
Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
2004 Jun
Complicated infections of skin and skin structures: when the infection is more than skin deep.
2004 Jun
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
2004 Jun
Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
2004 Jun
In vitro activity of ertapenem: review of recent studies.
2004 Jun
Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
2004 Jun
Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.
2004 Jun
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
2004 Jun
Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam.
2004 Mar
Gateways to clinical trials.
2004 Mar
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
2004 May 1
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
2004 Nov
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
2004 Oct
Gateways to clinical trials.
2004 Oct
Beta-lactam antibiotics: newer formulations and newer agents.
2004 Sep
Ertapenem: review of a new carbapenem.
2005 Feb
Ertapenem-associated seizures in a peritoneal dialysis patient.
2005 Feb
Distribution and characteristics of Escherichia coli clonal group A.
2005 Jan
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.
2005 Jun
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
2005 Mar
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
2005 May
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
2005 May
Characterization of a new integron containing bla(VIM-1) and aac(6')-IIc in an Enterobacter cloacae clinical isolate from Greece.
2005 May
Patents

Sample Use Guides

1 g given once a day. Intravenous infusion for up to 14 days or intramuscular injection for up to 7 days.
Route of Administration: Other
The MICs of ertapenem are MIC(50) = 0.032 μg/ml; MIC(90) = 0.064 μg/ml in vitro activity of ertapenem against N.gonorrhoeae isolates.
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:24:11 UTC 2021
Edited
by admin
on Fri Jun 25 22:24:11 UTC 2021
Record UNII
2T90KE67L0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERTAPENEM SODIUM
EMA EPAR   MART.   ORANGE BOOK   USAN   WHO-DD  
USAN  
Official Name English
ERTAPENEM SODIUM [WHO-DD]
Common Name English
(4R,5S,6S)-3-(((3S,5S)-5-((M-CARBOXYPHENYL)CARBAMOYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, MONOSODIUM SALT
Common Name English
MK-0826
Code English
ERTAPENEM SODIUM [USAN]
Common Name English
ERTAPENEM SODIUM [ORANGE BOOK]
Common Name English
1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-((5-(((3-CARBOXYPHENYL)AMINO)CARBONYL)-3-PYRROLIDINYL)THIO)-6-(1-HYDROXYETHYL)-4-METHYL-7-OXO-, MONOSODIUM SALT, (4R-(3(3S*,5S*), 4.ALPHA.,5.BETA.,6.BETA.(R*)))-
Common Name English
L-749345
Code English
ERTAPENEM SODIUM [MART.]
Common Name English
MK-826
Code English
ERTAPENEM SODIUM [EMA EPAR]
Common Name English
INVANZ
Brand Name English
ERTAPENEM SODIUM SALT [MI]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS INVANZ (AUTHORIZED: SURGICAL WOUND INFECTIONS)
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
NCI_THESAURUS C260
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
Code System Code Type Description
DRUG BANK
DBSALT001460
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY
RXCUI
353107
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C61753
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY
PUBCHEM
11145493
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY
ChEMBL
CHEMBL1359
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY
EVMPD
SUB16424MIG
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY
FDA UNII
2T90KE67L0
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY
CAS
153773-82-1
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY
MERCK INDEX
M5001
Created by admin on Fri Jun 25 22:24:11 UTC 2021 , Edited by admin on Fri Jun 25 22:24:11 UTC 2021
PRIMARY Merck Index
Related Record Type Details
TARGET ORGANISM->INHIBITOR
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY